The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Risankizumab-rzaa for PsA

FDA Approves Risankizumab-rzaa for PsA

April 20, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late January, the U.S. Food & Drug Administration (FDA) approved risankizumab-rzaa (Skyrizi) to treat adults with active psoriatic arthritis (PsA). This approval was supported by results from two clinical trials, KEEPsAKE-1 and KEEPsAKE-2.1

You Might Also Like
  • Risankizumab May Improve Symptoms of PsA
  • FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA
  • FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
Explore This Issue
May 2022
Also By This Author
  • Guselkumab Studied to Treat RA, Plaque Psoriasis

Both KEEPsAKE-1 (NCT03675308) and KEEPsAKE-2 (NCT03671148) are phase 3, placebo-controlled, efficacy and safety studies. Both studies also have a multicenter, randomized and double-blind design.2,3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

KEEPsAKE-1 evaluated risankizumab-rzaa in adults who had an inadequate response or intolerance to at least one conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), including leflunomide, sulfasalazine, apremilast or methotrexate.

KEEPsAKE-2 evaluated risankizumab-rzaa in adults who had an inadequate response or intolerance to biologic therapy and/or csDMARDs, such as methotrexate, sulfasalazine, leflunomide, apremilast, bucillamine, iguratimod or cyclosporine. (Note: Bucillamine and iguratimod are not FDA approved or available in the U.S.)

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in both trials were randomized to receive 150 mg of risankizumab-rzaa or placebo at weeks 0, 4 and 16, during the 24-week treatment period. The studies’ primary end point was the achievement of an ACR20 response at week 24. Also at week 24, some of the ranked secondary end points included a change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) and achievement of the Psoriasis Area and Severity Index (PASI) 90 response.

Results

In KEEPsAKE-1, 964 patients with active PsA were randomized in a 1:1 ratio to receive either risankizumab or placebo.2 At week 24, 57.3% of patients who received risankizumab-rzaa achieved the primary end point compared with 33.5% of patients who received placebo. This result was statistically significant (P<0.001). Significant differences were also found between patients who received risankizumab-rzaa and those who received placebo for the first eight ranked secondary end points, including skin and nail psoriasis, minimal disease activity and resolution of enthesitis and dactylitis (P<0.001).

At week 24, the ACR50 and ACR70 responses for patients who received risankizumab-rzaa were significantly improved compared with patients who received placebo. The percentage of patients treated with risankizumab-rzaa who achieved an ACR50 response was 33.4% compared with 11.3% of patients treated with placebo (P<0.001). The ACR70 response rates were 15.3% for the risankizumab-rzaa group and 4.7% for the placebo group (P<0.001).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Adverse events and serious adverse events were similar in both treatment groups. One death due to urosepsis was reported in a patient who received risankizumab-rzaa, but was deemed unrelated to the study drug.

In KEEPsAKE-2, 444 patients were randomized to receive risankizumab-rzaa (n=224) or placebo (n=220).3 Of these patients, 206 (46.5%) had previously had an inadequate response or intolerance to biologic agents. Secondary end points assessed key domains of PsA and patient-reported outcomes. Some of these included HAQ-DI PASI 90, proportion of patients achieving an ACR 20 at week 16, proportion of patients who achieved minimal disease activity (MDA) and change from baseline in 36-item Short Form Health Service Physical Component Summary (SF-36) score.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: FDA approval, PsA, Psoriatic Arthritis, risankizumab-rzaa, U.S. Food and Drug Administration (FDA)Issue: May 2022

You Might Also Like:
  • Risankizumab May Improve Symptoms of PsA
  • FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA
  • FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
  • Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)